Literature DB >> 15715560

Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology.

Torben Lykke Sørensen1, Per Haamann, Jørgen Villumsen, Michael Larsen.   

Abstract

PURPOSE: To evaluate the efficacy and safety of intravitreal triamcinolone in patients with macular oedema of varying aetiology.
METHODS: Two milligrams of intravitreal triamcinolone acetonide was injected into 34 eyes with persistent macular oedema (17 eyes with macula oedema secondary to posterior uveitis, 13 eyes with diabetic retinopathy, and four with pseudophakic macular oedema). Best corrected visual acuity was determined and transfoveal optical coherence tomography performed after 1 week, 1 month, 3 months and 6 months.
RESULTS: Treatment improved visual acuity and subjective visual quality, and reduced foveal thickness in eyes with posterior uveitis and eyes with macular oedema secondary to diabetic retinopathy. Eyes treated for pseudophakic cystoid macular oedema demonstrated no improvement. A total of 32% of patients experienced a significant post-injection increase in intraocular pressure. Endophthalmitis, rhegmatogenous retinal detachment and cataract were absent.
CONCLUSION: Intravitreal triamcinolone appears to induce marked a improvement in macular oedema secondary to non-infectious uveitis and diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15715560     DOI: 10.1111/j.1600-0420.2004.00336.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  9 in total

1.  Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations.

Authors:  Matthias Gutfleisch; Georg Spital; Anne Mingels; Daniel Pauleikhoff; Albrecht Lommatzsch; Arnd Heiligenhaus
Journal:  Br J Ophthalmol       Date:  2006-09-27       Impact factor: 4.638

2.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02

3.  Diabetic macular edema.

Authors:  Einar Stefánsson
Journal:  Saudi J Ophthalmol       Date:  2009-08-05

Review 4.  Physiology of vitreous surgery.

Authors:  Einar Stefánsson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-26       Impact factor: 3.117

5.  Perioperative Management of Uveitic Cataracts.

Authors:  Judy L Chen; Pooja Bhat; Ann-Marie Lobo-Chan
Journal:  Adv Ophthalmol Optom       Date:  2019-05-18

Review 6.  Clinical trials on corticosteroids for diabetic macular edema.

Authors:  Hassan A Al Dhibi; J Fernando Arevalo
Journal:  World J Diabetes       Date:  2013-12-15

7.  EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY.

Authors:  Pilar Calvo; Antonio Ferreras; Fadwa Al Adel; Wantanee Dangboon; Michael H Brent
Journal:  Retina       Date:  2018-03       Impact factor: 4.256

8.  Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants.

Authors:  Troels Brynskov; Caroline Schmidt Laugesen; Jakob Halborg; Henrik Kemp; Torben Lykke Sørensen
Journal:  Clin Ophthalmol       Date:  2013-06-13

9.  Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.

Authors:  Mariam El Filali; Irene Homminga; Willem Maat; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2008-09-24       Impact factor: 2.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.